+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Summit Therapeutics plc - logo

Summit Therapeutics is a biopharmaceutical company focussed on the development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile. The company is developing Ezutromid, an utrophin modulator product candidate that is in Phase II clinical trials used for to treat Duchenne muscular dystrophy disease. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

From
From
From
From
From
From
From
From
Klebsiella pneumoniae Infections - Pipeline Review, H2 2020 - Product Thumbnail Image

Klebsiella pneumoniae Infections - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 140 Pages
From
Acinetobacter Infections - Pipeline Review, H2 2020 - Product Thumbnail Image

Acinetobacter Infections - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 204 Pages
From
Duchenne Muscular Dystrophy - Global Clinical Trials Review, H2, 2021 - Product Thumbnail Image

Duchenne Muscular Dystrophy - Global Clinical Trials Review, H2, 2021

  • Clinical Trials
  • November 2021
  • 223 Pages
From
From
2021 Analytics of the Microbiome Landscape - Product Thumbnail Image

2021 Analytics of the Microbiome Landscape

  • Report
  • April 2021
  • 26 Pages
From
From
From
Loading Indicator